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Background: TransAtlantic Inter-Society Consensus (TASC) guideline recommended
femoro-popliteal (FP) bypass as standard treatment for TASC C-D lesions. Although
several studies have identified 5-year primary patency for FP bypass of around 70%,
complication rate is high compared with endovascular therapy (EVT). Accordingly,
EVT with nitinol stent implantation has been widely used for FP lesion. However,
long-term results of stenting, especially for TASC C-D lesions, remain unclear. Thus,
this study examined long-term outcomes of nitinol stent implantation for TASC C-D
FP lesions, factors associated with the restenosis and risk stratification according to
predictors.
Methods: Between December 2003 and December 2009, 381 patients with 471 TASC
C-D FP lesions (mean age 72.4 years; 67.5% male) underwent nitinol stent
implantation. Restenosis was defined either by duplex ultrasound or angiography.
Patency was analyzed by Kaplan-Meier estimation. Predictors for restenosis were
determined by Cox multivariate regression analysis, and primary patency rates were
compared between low or high risk groups that were created based on number of
predictors present.
Results: Mean lesion length was 230±65mm. At 6 years, the primary and secondary
patency rate and amputation-free survival rate was 51%, 77% and 72.7%, respectively.
By Cox multivariate regression analysis, female gender (hazard ratio [HR] 1.51; 95%
confidence interval [CI] 1.09-2.10; P=0.014), diabetes (HR 1.73; 95% CI 1.15-2.59;
P<0.01), claudicator (HR 1.73; 95% CI 1.15-2.59; P<0.01), without SMART stent
implantaion (HR 1.66; 95% CI 1.17-2.35; P<0.01), and reference vessel diameter <
6mm (HR 1.49; 95% CI 1.07-2.99; P=0.017) were the predictors for restenosis. Primary
patency in the low-risk group (number of risk factors 0-2) and high-risk group (3-5) at
6 years was 60.0% vs. 35.4%, p<0.0001, respectively.
Conclusion: EVT using nitinol stents yielded acceptable outcomes out to 6 years in
TASC C-D FP lesions. Revascularization strategy for TASC C-D lesions should be
chosen according to risk stratification.
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COMPLIANCE 360°: A Prospective, Randomized, Multicenter Trial
Comparing Balloon Angioplasty to Diamondback 360° Orbital Atherectomy
System in Calcified Femoropopliteal Disease
Raymond Dattilo
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Background: Stent placement in the distal superficial femoral and popliteal arteries
is associated with increased risk of stent fracture and restenosis. Lesion calcification
is predictive of vessel dissection and recoil after PTA. This study examines whether
the Diamondback 360° Orbital Atherectomy System (DB360) (Cardiovascular
Systems, Inc., St. Paul, MN), by changing the compliance of calcified femoropopliteal
(FP) lesions through the mechanism of differential sanding, diminishes the frequency
of adjunctive (bailout) stenting without sacrificing intermediate term patency.
Methods: 50 symptomatic patients (66 lesions) from 10 sites with calcified FP lesions
of ≥70% were equally randomized to PTA alone vs. DB360 followed by low pressure
PTA up to 4 atmospheres (atm) with the endpoint of residual stenosis ≤30%. Lesions
failing to achieve this endpoint with the prescribed therapy were then treated with
bailout stenting. Freedom from target lesion revascularization (TLR), including the
need for bailout stenting, or restenosis defined as a peak systolic velocity ratio of ≥2.5
on duplex study at 6 months, was the primary endpoint.
Results: 92.1% of 38 lesions in the DB360 arm and 21.4% of 28 lesions in the PTA
arm (p<0.0001) met the angiographic endpoint after primary therapy. 2 of 25 pts in the
DB360 arm vs. 21 of 25 pts in the PTA arm required bailout stenting (p<0.0001). Mean
maximum balloon pressure (a measure of lesion compliance) in the DB360 arm was
3.9 atm vs. 8.5 atm in the PTA arm (p<0.0001). At 6 months, 4 pts in the DB360 arm
vs. 3 pts in the PTA arm had restenosis (p=NS); 2 of 3 in the PTA arm were in-stent.
Freedom from TLR or restenosis at 6 months was 72.7% (16 of 22 pts) in the DB360
arm and 8.3% (2 of 24 pts) in the PTA arm (p<0.0001).
Conclusion: Compared to PTA alone, orbital atherectomy with low pressure PTA leads
to better luminal gain by improving lesion compliance with less need for adjunctive
stenting when treating calcified FP lesions. Patency at 6 months is comparable to PTA
with a provisional stent strategy.
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Background: Renal denervation was found to be effective in drug-resistant
hypertension. Here we dscribe the results of the first 31 patients treated outside the
study criteria regarding reduction of drug intake and effectiveness.
Methods: Between Mai 2010 and January 2011 31 patients were treated with the
Ardian simplicity system. These patients were followed for 6 months with repetitive
diabetes and hypertension monitoring. No side-effects related to the ablation were
documented. Patients were required to have at least 3 medications on board to be
eligible; systolic blood press was measured at least once > 160 mmHg. In addition,
echo criteria regarding diastolic dysfunction, HbA1c as a measure of glycemia control
as well as renal function were closely monitored.
Results: After a 6 months follow up, 65% of patients responded to the therapy with
either a measurable drop in blood pressure measured at the oupatient follow up visit 3
months after the procedure (35%) and/or less dyspnoe on exertion. 16% of patients
reduced their medication in part due to dizziness with the newly decreased blood
pressure. No effect on HbA1c was detected in this cohort; HbA1 was > 5.9% in 55%
of patients. No measurable effect on diastolic dysfunction was found during the above
mentioned follow up period of 6 months.
Conclusion: Renal denervation was found safe and partially effectived; we have since
altered our system. Re-evaluating the patients who did not respond to treatment suggest
duration of hypertensive treatment to be an independent predictor.
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Acute And Long-term Follow-up Results Of Renal Angioplasty In Takayasu
Arteritis
Amar Narayan Patnaik, D. S Rao, B. Srinivas
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Background: Takayasu arteritis frequently presents with hypertension in young adults.
Stenosis of one or both renal arteries is present in most of them and angioplasty of
these lesions is expected to control hypertension and control renal damage. We present
the acute and long term results of renal angioplasty done for the last 8 years in our
hospital.
Methods: All cases of Takayasu arteritis, diagnosed basing on criteria suggested by
Ishikawa, who underwent percutaneous transluminal renal angioplasty (PTRA) in our
hospital from 2003 were followed up clinically and by a renal Doppler in all cases at
all visits. A cine renal- angiogram was advised at 6 months and 18 month visit. During
2003 to 2008, we performed renal angioplasty in 85 lesions (76 patients; 54 females;
age range 24 to 47 years; mean 29.5±5.65 years). Unilateral lesions were seen in 67
patients and rest had one lesion in each kidney. Ostial lesions constituted % (29/85) of
the cases. Of them 64 cases who had at least 18 months follow-up data were included
for analysis.
Results: Results: Technical success rate for the first PTRA was 90.5% )( 77/85) lesions.
Of the 8 failure cases one with bilateral lesions was sent for emergency surgery due to
renal artery rupture following PTRA and 5 underwent surgical revascularization. Of
the ostial lesions technical success rate was 68.9 % (21/29). There was no mortality in
any case. On a mean follow up of 22.5±8.55 months 19 of 64 cases {23 of 66 lesions
(34.8%)} developed restenosis and 17 of them were successfully redilated. There was
death of one patient with bilateral lesions due to CRF. Cure of hypertension (BP
<140/90 mmHg without need for medication) and improvement (BP<140/90 mmHg
with same or reduced number of medications) was achieved in 25/64(39%) and
24/64(37.5%) respectively. Of the 25 cases with raised serum creatinine 17/25 (68%)
had shown a fall in their values in follow-up (mean 1.91± 1.05mg to 1.3±0.76 mg; p-
<0.005)
Conclusion: PTRA is technically feasible with acceptable acute results. Ostial lesions
are more difficult to be dilated. The restenosis is seen in about one-third of the cases
after successful procedure which can be redilated. Control of hypertension and renal
dysfunction is achieved in a significant number of cases.
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Impact of Preexisting Cerebral Ischemia Detected by Magnetic Resonance
Imaging and Angiography on Clinical Outcomes After Coronary Artery Bypass
Graft in Patients Without History of Stroke
Won-Jang Kim, Sun-Joo Jang, Yong Kyu Park, Gyung-Min Park, Yong-Giun Kim,
Jung-Min Ahn, Jong-Young Lee, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee,
Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
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Background: Limited data existed for long-term clinical outcomes of asymptomatic
brain ischemia after coronary artery bypass grafting (CABG). We sought to assess the
impact of preexisting ischemia detected by brain magnetic resonance imaging and
angiography (MRA) on clinical outcomes after CABG.
Methods: Between Jan. 2003 and May 2009, 3,071 patients underwent CABG in Asan
Medical Center. Preoperative brain MRA was performed in 2,417 patients. Patients
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